SCHEMBL21296944

SCHEMBL21296944

CCOC(=O)c1nn[nH]c1Sc1ccccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.56
LMNA P02545 2/20 0.56
NPSR1 Q6W5P4 3/20 0.54
HPGD P15428 1/20 0.48
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 3/20 0.42
POLB P06746 2/20 0.42
HTT P42858 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ALOX5 P09917 3/20 0.40
TP53 P04637 1/20 0.39
ALOX12 P18054 1/20 0.39
MAPK1 P28482 1/20 0.39
PDE4B Q07343 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CYP19A1 P11511 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799115 1.00 MAPT (0.56) MAPTLMNANPSR1HPGDKDM4E
SCHEMBL29799098 0.85 KDM4E (0.43) MAPTLMNANPSR1KDM4EALDH1A1
SCHEMBL21296980 0.85 KDM4E (0.43) MAPTLMNANPSR1KDM4EALDH1A1
SCHEMBL21296875 0.80 PKM (0.46) MAPTLMNANPSR1HPGDALDH1A1
SCHEMBL29799229 0.80 PKM (0.46) MAPTLMNANPSR1HPGDALDH1A1
SCHEMBL21296915 0.80 ALPL (0.47) MAPTNPSR1KDM4EALDH1A1HTT
SCHEMBL21296903 0.75 MAPT (0.44) MAPTNPSR1KDM4EPOLBHTT
SCHEMBL28429182 0.74 MAPT (0.67) MAPTLMNANPSR1HPGDKDM4E
SCHEMBL21296967 0.74 NPC1 (0.48) MAPTLMNANPSR1HPGDKDM4E
SCHEMBL23001880 0.74 CYP19A1 (0.43) MAPTNPSR1KDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX MAPT 1559/4885LMNA 3347/4885NPSR1 3194/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX MAPT 1559/4885LMNA 3347/4885NPSR1 3194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.